Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance.
Issue Date
2021-05-18Keywords
COVID-19FRAX
osteoporosis
Osteoporosis management
Metadata
Show full item recordJournal
Calcified tissue internationalDOI
10.1007/s00223-021-00858-9PubMed ID
34003337Item Type
ArticleLanguage
enEISSN
1432-0827ae974a485f413a2113503eed53cd6c53
10.1007/s00223-021-00858-9
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- State of Fragility Fractures Management during the COVID-19 Pandemic.
- Authors: Tarantino U, Cariati I, Tancredi V, Casamassima D, Piccirilli E, Iundusi R, Gasbarra E
- Issue date: 2020 Oct 22
- Osteoporosis Management in the Era of COVID-19.
- Authors: Yu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT
- Issue date: 2020 Jun
- Effects of bone remodeling agents following teriparatide treatment.
- Authors: Burkard D, Beckett T, Kourtjian E, Messingschlager C, Sipahi R, Padley M, Stubbart J
- Issue date: 2018 Jun
- Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
- Authors: Kamata Y, Minota S
- Issue date: 2019 Jul 31
- Using Osteoporosis Therapies in Combination.
- Authors: McClung MR
- Issue date: 2017 Aug